These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16488339)

  • 1. Relapse, rebound, and psoriasis adverse events: an advisory group report.
    Carey W; Glazer S; Gottlieb AB; Lebwohl M; Leonardi C; Menter A; Papp K; Rundle AC; Toth D
    J Am Acad Dermatol; 2006 Apr; 54(4 Suppl 1):S171-81. PubMed ID: 16488339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy.
    Costanzo A; Talamonti M; Spallone G; Botti E; Chimenti MS; Papoutsaki M; Chimenti S
    Dermatology; 2009; 218(2):146-50. PubMed ID: 18971577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efalizumab-induced guttate psoriasis. Successful management and re-treatment.
    Balato A; La Bella S; Gaudiello F; Balato N
    J Dermatolog Treat; 2008; 19(3):182-4. PubMed ID: 18569275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efalizumab, a reversible T-cell modulator for psoriasis.
    Shear NH; Langley RG; Ho V
    J Cutan Med Surg; 2006; 9 Suppl 1():4-9. PubMed ID: 16633862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efalizumab: a biological agent for the treatment of psoriasis.
    Hodulik S; Hadi S
    Rev Recent Clin Trials; 2006 May; 1(2):165-8. PubMed ID: 18473968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis.
    Papp KA; Ho V; Langley R; Lynde C; Poulin Y; Shear N; Toole J; Zip C
    J Cutan Med Surg; 2006; 9 Suppl 1():26-32. PubMed ID: 16633859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A favourable benefit/risk ratio with efalizumab: a review of the clinical evidence.
    Poulin Y; Papp KA; Carey W; Gulliver W; Gupta AK
    J Cutan Med Surg; 2006; 9 Suppl 1():10-7. PubMed ID: 16633861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
    Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
    J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efalizumab: integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis.
    Lynde C
    J Cutan Med Surg; 2006; 9 Suppl 1():1-3. PubMed ID: 16633863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efalizumab: new drug. Plaque psoriasis: too many unknowns.
    Prescrire Int; 2006 Feb; 15(81):8-11. PubMed ID: 16548097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
    Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
    Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.
    Leonardi CL; Papp KA; Gordon KB; Menter A; Feldman SR; Caro I; Walicke PA; Compton PG; Gottlieb AB;
    J Am Acad Dermatol; 2005 Mar; 52(3 Pt 1):425-33. PubMed ID: 15761420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rebound of psoriasis after efalizumab discontinuation, despite being on high-dose cyclosporine.
    Maskatia ZK; Koo J
    J Drugs Dermatol; 2007 Sep; 6(9):941-4. PubMed ID: 17941368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exacerbation of psoriasis under efalizumab therapy.
    Rallis E; Verros C; Karanikola E; Valaskatzi A; Papaconstantis M
    J Cutan Med Surg; 2009; 13(2):106-9. PubMed ID: 19298780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical management with efalizumab of a patient with psoriasis and comorbid vitiligo.
    Fernandez-Obregon AC
    J Drugs Dermatol; 2008 Jul; 7(7):679-81. PubMed ID: 18664161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for incorporating biologicals into management of moderate to severe plaque psoriasis: individualized patient approaches.
    Langley RG; Ho V; Lynde C; Papp KA; Poulin Y; Shear N; Toole J; Zip C
    J Cutan Med Surg; 2006; 9 Suppl 1():18-25. PubMed ID: 16633860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psoriasis vulgaris flare during efalizumab therapy does not preclude future use: a case series.
    Lowes MA; Turton JA; Krueger JG; Barnetson RS
    BMC Dermatol; 2005 Aug; 5():9. PubMed ID: 16109173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efalizumab: Advancing psoriasis management with a novel, targeted T-cell modulator.
    Papp KA
    Drugs Today (Barc); 2004 Nov; 40(11):889-99. PubMed ID: 15645002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.